EUVIMEDEUVIMED entdecken
Open Access

Path sampling challenges in large biomolecular systems: RETIS and REPPTIS for ABL-imatinib kinetics

Wouter Vervust, Daniel T Zhang, Enrico Riccardi, Titus S van Erp, An Ghysels

Biophysical Journal · 2025

DOI: 10.1016/j.bpj.2025.04.020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biophysical Journal, 2025. Verfasst von Wouter Vervust und 4 weiteren Autor:innen. Beteiligte Einrichtung: IBiTech - BioMMedA Research Group, Ghent University, Gent, Belgium. Hauptthemen laut MEDLINE: Imatinib Mesylate, Proto-Oncogene Proteins c-abl, Molecular Dynamics Simulation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: European Commission, Vlaams Supercomputer Centrum, European Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Predicting the kinetics of drug-protein interactions is crucial for understanding drug efficacy, particularly in personalized medicine, where protein mutations can significantly alter drug residence times. This study applies replica exchange transition interface sampling and its partial path variant to investigate the dissociation kinetics of imatinib from Abelson nonreceptor tyrosine kinase (ABL) and mutants relevant to chronic myeloid leukemia therapy. These path sampling methods offer a bias-free alternative to conventional approaches requiring qualitative predefined reaction coordinates. Nevertheless, the complex free energy landscape of ABL-imatinib dissociation presents significant challenges. Multiple metastable states and orthogonal barriers lead to parallel unbinding pathways, complicating convergence in transition interface sampling-based methods. Despite employing computational efficiency strategies such as asynchronous replica exchange, full convergence remained elusive. This work provides a critical assessment of path sampling in high-dimensional biological systems, discussing the need for enhanced initialization strategies, advanced Monte Carlo path generation moves, and machine learning-derived reaction coordinates to improve kinetic predictions of drug dissociation with minimal prior knowledge.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Imatinib MesylateProto-Oncogene Proteins c-ablMolecular Dynamics SimulationKineticsHumansMonte Carlo MethodThermodynamics

Substanzen

Imatinib MesylateProto-Oncogene Proteins c-abl

Autor:innen und Institutionen

  • IBiTech - BioMMedA Research Group, Ghent University, Gent, Belgium.
  • Research Institute for Interdisciplinary Science, Okayama University, Okayama, Japan.
  • Department of Energy Resources, University of Stavanger, Stavanger, Norway.
  • Department of Chemistry, Norwegian University of Science and Technology, Trondheim, Norway.
  • IBiTech - BioMMedA Research Group, Ghent University, Gent, Belgium. Electronic address: an.ghysels@ugent.be.

Förderung

  • European Commission
  • Vlaams Supercomputer Centrum
  • European Research Council
  • Vlaamse regering
  • Universiteit Gent
  • Fonds Wetenschappelijk Onderzoek
  • Vermont Studio Center
  • HORIZON EUROPE European Research Council

Zitieren

APA

Vervust, W., Zhang, D. T., Riccardi, E., van Erp, T. S., & Ghysels, A. (2025). Path sampling challenges in large biomolecular systems: RETIS and REPPTIS for ABL-imatinib kinetics. Biophysical Journal. https://doi.org/10.1016/j.bpj.2025.04.020

Vancouver

Vervust W, Zhang DT, Riccardi E, van Erp TS, Ghysels A. Path sampling challenges in large biomolecular systems: RETIS and REPPTIS for ABL-imatinib kinetics. Biophysical Journal. 2025. doi:10.1016/j.bpj.2025.04.020

BibTeX
@article{Vervust2025,
  author = {Vervust, Wouter and Zhang, Daniel T and Riccardi, Enrico and van Erp, Titus S and Ghysels, An},
  title = {Path sampling challenges in large biomolecular systems: RETIS and REPPTIS for ABL-imatinib kinetics},
  journal = {Biophysical Journal},
  year = {2025},
  doi = {10.1016/j.bpj.2025.04.020}
}
Kostenlos starten →